Industry: Pharmaceuticals, Biotechnology
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company’s three lead product candidates are: DCVax® -Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax® -Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and CXCR4 a therapeutic monoclonal antibody in late preclinical development for the treatment of cancer. ( www.nwbio.com )
Northwest Biotherapeutics , Inc.
21720 23Rd Drive Se Suite 100
Bothell, Washington 98021
USA
Tel: (425) 608-3000
Fax: (425) 608-3026